ROS1-Targeting Lung Cancer Drug Yields 90% Response Rate

(MedPage Today) -- Most patients with advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who had not previously received a tyrosine kinase inhibitor (TKI) had an objective response with zidesamtinib (Jideytro), according to...